Sol Barer, Director at Aevi Genomic Medicine, holds 277.43K shares in Teva Pharmaceutical Industries (Ticker: TEVA), holds 0.00 shares in Aevi Genomic Medicine (Ticker: GNMX), holds 775.93K shares in ContraFect (Ticker: CFRX).
Sol Barer latest transaction was an Uninformative Buy of ―.
What was Sol Barer's most profitable transaction?
Sol Barer’s most profitable transaction was an Informative Buy of CFRX stock on July 26, 2017. The return on the trade was 75.20%.
What is Sol Barer's role in Aevi Genomic Medicine?
Sol Barer's role in Aevi Genomic Medicine is Director.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.